Add Yahoo as a preferred source to see more of our stories on Google. Moderna and MSD's mRNA cancer vaccine A combination of Moderna and MSD's personalised cancer vaccine, intismeran autogene, and MSD ...
IO102-IO103 plus Keytruda improved median PFS by 8.4 months over Keytruda alone in advanced melanoma patients. The combination therapy showed a significant PFS benefit in PD-L1–negative patients, with ...
Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals promising five-year results.
(RTTNews) - IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with Merck & Co Inc.'s (MRK) ...
Moderna Inc. (NASDAQ: MRNA) and Merck & Co. Inc. (NYSE: MRK) on Tuesday shared median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study of ...
Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, reduced the risk of tumor recurrence or death by 49% over five years in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results